Detalhe da pesquisa
1.
Combined therapy with CD4+ CD25highCD127- T regulatory cells and anti-CD20 antibody in recent-onset type 1 diabetes is superior to monotherapy: Randomized phase I/II trial.
Diabetes Obes Metab
; 24(8): 1534-1543, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35441440
2.
Factors affecting long-term efficacy of T regulatory cell-based therapy in type 1 diabetes.
J Transl Med
; 14(1): 332, 2016 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27903296
3.
PD-1 Receptor (+) T cells are associated with the efficacy of the combined treatment with regulatory t cells and rituximab in type 1 diabetes children via regulatory t cells suppressive activity amelioration.
Int Immunopharmacol
; 132: 111919, 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38554443
4.
Proinsulin-specific T regulatory cells may control immune responses in type 1 diabetes: implications for adoptive therapy.
BMJ Open Diabetes Res Care
; 8(1)2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32098895
5.
Assessing the knowledge of the consequences of uncontrolled diabetesin pregnancy and its effects on fetal development, among femaleadolescents with type 1 diabetes.
Pediatr Endocrinol Diabetes Metab
; 23(4): 188-196, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29574471
6.
[Insulin secretion in the early phase of type 1 diabetes mellitus (T1DM) and new hopes for maintaining it through therapy]. / Insulinosekrecja we wczesnej fazie cukrzycy typu 1 i nowe nadzieje terapeutyczne na jej utrzymanie.
Pediatr Endocrinol Diabetes Metab
; 22(3)2016.
Artigo
em Polonês
| MEDLINE | ID: mdl-28633161